Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (267)	2/6/2007 1:10:31 PM
From: Steve Lokness	Read Replies (2) \| Respond to of 360

<<ust listkeeping. Sure, if Caliper/Xenogen continues to allow Gene Logic use of the glow in the dark mice and their imaging machines and such, super.>> The MC of GLGC is now a little over 50 million - at least it is positive <smile>. I read this morning that GLGC sunk 150 million into their tissue bank, which I assume they still have and is active in their repositioning targets? If they can merge the information gleamed from the tissue bank with live cell changes achived through one of the machines - read XGEN - it just feels to me they are one "mouse" click away from a successful target. Kind of blurring the discussion between CALP and GLGC, but maybe that is not a bad thing? steve

To: Mike McFarland who wrote (267)	6/19/2007 12:36:06 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

Trying to remember Melior/listkeeping COMPETITION Drug Repositioning Division Currently, an increasing number of pharmaceutical and biotechnology companies are evaluating whether to implement internal repositioning programs for their own drug candidates. In addition, there are companies attempting to reposition drug candidates on behalf of drug development partners, including Melior, KineMed, Perlegen Sciences, Inc., Vanda Pharmaceuticals Inc. and CombinatoRX Inc. We are not aware of any existing competitor that has developed, or is in the process of developing, a comparable suite of technologies to that employed by us. Other companies, some of whom are not doing repositioning work, have individual technologies that could directly compete with components of our drug repositioning technology platform. and many listed here: genengnews.com including quite a few I've never heard of such as ActivX, AnalytiCon, Arachnova, Astellas and Asterand and that is just the A's